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Views & Reviews 
Chronic lymphocytic leukemia 
and the central nervous system: 
A clinical and pathological study 
Steven C. Cramer, MD; John A. Glaspy, MD, MPH; J immy T. Efird, MS, RC, CSP; and David N. Louis, MD 
Article abstract-chronic lymphocytic leukemia is the most common human leukemia but infrequently causes neuro- 
logic symptoms. We have reviewed all previously reported cases of chronic lymphocytic leukemia in the CNS along with 
three new cases; one patient was diagnosed antemortem and treated with immediate improvement and 4-year survival. In 
addition, we reviewed all autopsy cases since 1972 and available lumbar puncture data on patients with chronic lympho- 
cytic leukemia admitted to  the Massachusetts General Hospital. Invasion of the CNS by chronic lymphocytic leukemia 
often leads to confusional state, meningitis with cranial nerve abnormalities, optic neuropathy, or cerebellar dysfunction. 
Lumbar puncture shows a lymphocytosis consisting of monoclonal B cells, but CSF cytology studies are of limited value in 
establishing the diagnosis. Long-term survival may be related to the stage of chronic lymphocytic leukemia a t  the time of 
CNS disease and may be associated with intrathecal chemotherapy. A mild, asymptomatic infiltration of the brain, 
frequently noted in late-stage chronic lymphocytic leukemia in autopsy series, may explain the CSF lymphocytosis in some 
patients with late-stage chronic lymphocytic leukemia. 
NEUROLOGY 1996;46: 19-25 
Chronic lymphocytic leukemia (CLL), the most com- 
mon human leukemia the United States,' is an indo- 
lent  disease that principally affects the elderly, 
whose median age at diagnosis is 602 and whose 
average survival is 6 years from the time of diagno- 
s ~ s . ~  Only a small percentage of patients progress to  
a more malignant phen~type.~.~ Although there are 
many reports of CLL involvement of the peripheral 
nervous system, including peripheral neur0pathy,6-~ 
facial nerve p a l ~ y , l ~ - ' ~  acoustic n e ~ r o p a t h y , ' ~  femoral 
neuropathy, lo and epidural compression of the spinal 
c ~ r d , ~ J * J ~  symptomatic invasion of the CNS by CLL 
has only rarely been reported. In autopsy series,l6-lg 
however, infiltration of the brain or spinal cord is 
common in CLL, but patients are asymptomatic. 
Thus, despite the diagnosis of 200,000 cases of CLL 
in the United States in the last 20 years,2o there are 
only 18 reported cases causing CNS manifestations. 
In this study, we document a case of successfully 
treated CNS CLL and review the literature on previ- 
ously reported cases of CLL infiltration of CNS. In 
addition, we describe the pathological details of all 
CLL patients autopsied at the Massachusetts Gen- 
eral Hospital (MGH) since 1972. To address the issue 
raised by autopsy studies of clinically silent infiltra- 
tion of CNS by CLL, we also reviewed lumbar  punc- 
ture results from 18 unselected CLL patients. 
Methods. Review of pathology. Between 1972 and 
1994, 83 patients with CLL died at MGH. Review of avail- 
able charts and autopsy records disclosed 21 autopsies, 16 
with CNS examination, which we studied (table 1). CNS 
CLL was diagnosed whenever abnormal numbers of ma- 
ture or atypical lymphocytes were seen in the subarach- 
noid space or brain parenchyma, in the absence of an alter- 
native explanation.z1 
Literature review. We only included cases of CNS CLL 
that met the following criteria: (1) a diagnosis of CLL; (2) a 
pleocytosis of predominantly lymphocytes in CSF or in the 
subarachnoid space on pathologic examination of the CNS; 
plus either (3a) histopathology highly suggestive of infil- 
tration by CLL in the absence of an alternative explana- 
tion, (3b) predominantly B lymphocytes, preferably estab- 
lished as monoclonal, in the CSF, or (3c) a response to 
intrathecal chemotherapy andor x-ray therapy, which was 
immediate and sustained. Use of the term CLL in this 
paper refers to the B-cell variety, as this accounts for 98% 
of CLL in the United  state^.^ Using these criteria, several 
patients could not be included (Korsager et al,22 patient 2; 
Leidler and patient 16; Poltorak et a P ;  Diwan et 
alZ5; Pandolfi et a P ;  and Diam~nd,"~ patient 12). 
Data on lumbar punctures 
performed on patients with CLL at MGH were identified 
during a review of the charts for pathology or from a re- 
view of laboratory data since 1988 on MGH patients with 
CLL. 
Lumbar puncture reuiew. 
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Table Z Neuropathologic findings of 12 autopsy cases with CLL a t  Massachusetts General Hospital since 1972 
Age at  Rai 
Case no. death (yr) stage Last WBC Clinical findings Cause of death Other CLL ( + ) organs Neuropathology 
A1 
A2 
A3 
A4 
A5 
A6 
A7 
A8 
A9 
A10 
A1 1 
A12 
~ 
67 
59 
81 
78 
77 
59 
53 
63 
87 
69 
63 
69 
~ 
111 
Iv 
I1 
IV 
0 
IV 
I1 
IV 
0t 
I 
I1 
!x 
29,000 
300 
42,000 
7,000 
15,000 
386,000 
2,000 
111,000 
14,000 
15,000 
13,000 
4,000 
Neuro WNL Renal failure 
Confusion, left toe Sepsis 
Left VII palsy, Pneumonia 
UP, MRI ( -  ) 
dysmetria, 
dementia, CT I - ); 
IgG K paraprotein 
Neuro WNL Pneumonia 
Spleen, lymph nodes, ( - )  
( - )  Cerebral edema, 
Lymph nodes, liver, 
liver, kidneys 
subdural effusions 
Diffuse Lewy body 
spleen, bone disease 
marrow 
Bone marrow, spleen, ( -  ) 
lymph nodes 
Ataxia; weak ankles, Pneumonia ( - )  
loss of vibration 
sense 
Cells blastic in final CHF and pneumonia Bone marrow, liver, 
mos, neuro W L  spleen, kidney, 
lungs, larynx, 
heart, adrenals, 
periosteum 
Prior x-ray therapy Listeria monocytogenes Scalp; CLL and 
hygromas on CT 
Neuro WNL 
14-mo history of lung 
cancer: neuro WNL 
Cells blastic in final 
mos; mild, diffuse 
weakness 
Gastrointestinal 
bleeding 
Sepsis 
Sepsis 
to parotid meningitis 
lymphoma; 
confused 
Neuro WNL; Lymphoma 
transformed to 
lymphoma 
(Richter’s 
syndrome) 
m t a t e d ;  bilateral Strangulated hernia 
~ 
lymphoma in lymph 
nodes and lungs 
DWDL and large cell 
lymphoma in liver 
and spleen; former 
also in nodes 
Prostate, lungs, bone 
marrow, liver, 
kidneys, spleen 
Lymph nodes, spleen, 
kidneys 
Bone marrow, spleen, 
liver; lung cancer in 
braidother sites 
Spleen, lymph nodes, 
bone marrow, liver, 
kidneys 
Cortical atrophy, 
hydrocephalus 
Lymphocytes in brain 
and Virchow-Robin 
space; areas of recent 
ischemic change (see 
figure 1) 
meningitis, early 
cerebral infarcts 
Changes of acute 
Subdural ecchymoses 
Clusters of subarachnoid 
lymphocytes (see 
figure 2), lacunae, 
subdural hygromas, 
Alzheimer’s disease 
( - 1  
Large-cell lung cancer 
metastasis 
Some subarachnoid 
lymphocytes with 
normal appearance 
t Diagnosis of CLL made a t  autopsy 
WBC = white blood cell count; CLL = chronic lymphocytic leukemia; WNL = examination within normal limits; IgG = immunoglobu- 
lin G; CHF = congestive heart failure; DWDL = diffuse well-differentiated lymphocytic. 
Statistical analysis. The Kaplan-Meier product-meth- 
odZX was used to estimate survival probabilities, with sta- 
tistical inferences on actuarial curves made using the log- 
rank test.2Y Six patients who did not die, but who lacked at 
least 1 year of followup, were excluded from survival anal- 
ysis. 
Case Report. A 62-year-old woman (see table 2, case 
C21) presented to UCLA Center for Health Sciences with 
complaints of left ear hearing loss, weakness, poor balance, 
and unsteady gait. Twelve days before admission, her 
white blood cell (WBC) count was 35,000 and her physical 
examination was unremarkable. A diagnosis of CLL had 
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been made 2 years before and she had received no therapy, 
remaining Rai stage 0.3 Her past medical history was sig- 
nificant for bilateral myringotomies with tube placement 3 
years before, and she had been treated with oral ampicillin 
for 2 days before admission. 
She had a temperature of 373°C. A physical examina- 
tion showed a serous otitis media and a mass on the left 
auditory canal wall; no lymphadenopathy or hepatospleno- 
megaly was noted. Neurologic examination disclosed nor- 
mal mental status. Funduscopy was normal. She had four 
beats of lateral nystagmus on end-point gaze to the left 
and to the right and intermittent ptosis. Deep tendon re- 
flexes were 3+ with normal tone and bilateral extensor toe 
Figure 1. Case A6. In a patient with chronic lymphocytic 
leukemia who underwent a blastic transformation, lym- 
phocytes with a malignant appearance f i l l  a subcortical 
blood vessel and the Virchow-Robin space (Luxol fast blue, 
hematoxylin and eosin, X250). 
responses. Motor and sensory examinations revealed only 
decreased vibration in her feet. An intention tremor of the 
upper extremities was more marked on the left, and heel- 
to-shin testing was normal. Her gait was wide based and 
ataxic; tandem gait was poor. Barany’s tests were nega- 
tive. Her laboratory results were significant for a WBC of 
98,000, including 91% lymphs, 4% segs, and 3% bands. 
Peripheral smear lymphocytes were predominantly mature 
with less than 3% immature forms. Hemoglobin was 12.2 
g/dl with platelets of 313,000/mm3. A contrast-enhanced 
CT scan of the brain was interpreted as diffuse swelling of 
the cortex and cerebellum with small, enhancing lateral 
ventricles and a slit-like fourth ventricle. Opacification 
was noted in the left middle, but not inner, ear. 
Intravenous dexamethasone, cefuroxime, and ampicillin 
were begun, and she quickly defervesced. Myringotomy 
cultures were negative and the left ear masslotitis media 
improved markedly with antibiotics, but before methotrex- 
ate. Lumbar puncture performed on hospital day 1 was 
traumatic. Lumbar punctures on days 3 and 5 showed 
normal opening pressures, glucose ratios, and protein and 
a WBC count that fell from 260/mm3 to 135/mm3, all lym- 
phocytes in both cases. Extensive microbiological studies 
were negative. Atypical lymphocytes were noted on cytol- 
ogy studies. Immunocytochemical studies of CSF and pe- 
ripheral blood lymphocytes showed a clonal population of 
immunoglobulin G (+), K light chain ( f  ) B cells. After the 
second and third lumbar punctures, 12 mg of methotrexate 
in 10 ml of Elliot’s B solution was given intrathecally. Her 
neurologic examination became normal over 7 days and 
the patient was discharged. Her subsequent total intra- 
thecal therapy was six doses of 12 mg of methotrexate and 
one dose of 100 mg of cytarabine (Ara-C) over an 8-week 
period. A lumbar puncture done 26 days after admission 
was normal. She then received 4000 cGy of cranial x-ray 
therapy. 
Two years later, she was placed on chlorambucil for 
anemia. Four years after her CNS symptoms were treated, 
her WBC count rose to 225,000 with increased numbers of 
immature cells. A bone marrow biopsy showed small, 
cleaved, follicular center-cell lymphoma with evolution to 
large-cell lymphoma, and chemotherapy was started. She 
then presented with a fever and multiple abdominal 
masses. She could not follow one-stage commands, al- 
though her neurologic examination was otherwise unre- 
markable. A noncontrast head CT scan was normal, and a 
lumbar puncture was normal with negative cytology. The 
patient’s death was ascribed to transformation of CLL to a 
malignant large-cell lymphoma (Richter’s syndrome). No 
autopsy was performed. 
Results. The neuropathology findings from the 12 autop- 
sied patients with CLL at MGH with available microscopic 
sections are described in table 1; no gross diagnostic abnor- 
malities were recorded and no microscopic sections were 
taken in four cases. Infiltration of CNS by CLL cells was 
noted in two cases: one, Rai stage IV (case A6, figure 1) 
and the other, Rai stage 0 (case A9, figure 2). The degree of 
infiltrationz1 was grade IIUIII for case A6 and grade MI1 
for case A9. An aggressive transformation of the CLL was 
noted in cases A6, AS, and A12, whereas case A7 was 
associated with a recurrent lymphoma. The spinal cord 
was included in only one autopsy (case A12). 
Table 2 illustrates the clinical features for the 18 re- 
ported patients from the literature and our three cases of 
CLL in the CNS. CNS involvement occurs across all stages 
of CLL, with a median age of 63 years (range, 38-87) and 
Figure 2. Case A9. This patient was diagnosed with 
chronic lymphocytic leukemia at autopsy. Scattered clus- 
ters of atypical-appearing lymphocytes in Virchow-Robin 
space (Luxol fast blue, hematoxylin and eosin, X 790). 
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Table 2 Clinical characteristics of patients with CLL in the CNS 
-~ 
Rai 
stage 
Patient 
no. CSF WBC (celldmm3) Treatment Course Clinical findings 
Headache, confusion, 
- ~~ 
reverse ocular bobbing; 
suprasellar lesion on CT 
Headache, fever 
~ 1 3 1 ~  
c231 
C33' 
C412 
c532 
C6'3 
c733 
C8" 
c911 
c 1034 
c1135 
~1236 
C1337 
C14?* 
C151q 
C164u 
C17" 
C1W 
c19 
c20 
c 2 1  
-._ 
0 
N 
N 
I1 
I1 
I11 
I11 
Iv 
0 
0 
I1 
0 
I1 
I11 
I1 
N 
0 
N 
N 
0 
0 
Lymphs; protein 600 VP shunt Died on postoperative day 
10 
253 WBC; 100% lymphs XRT and it MTX Died of cardiac causes 
after 5 asymptomatic 
mo 
Symptom free at 30 mo 
Transiently improved with 
XRT, died a t  7 mo 
Disease free a t  1 mo; died 
of sepsis at 1 year 
Died at 10 mo of trauma 
Stable a t  9 mo 
XRT improved symptoms; 
died at  13 mo of lung 
process 
No symptoms a t  20 mo 
Fever, right VI palsy 
2 years dementia 
80 WBC; 100% lymphs 
257 WBC; 100% lymphs 
170 WBC; 100% lymphs 
25 WBC; 100% lymphs 
21 WBC; 100% lymphs 
LymPhS 
it MTX 
XRT and it MTX 
XRT and it MTX 
XRT to optic nerve 
XRT to optic nerve 
XRT to optic nerve 
Fever, infiltrate in sinuses 
10 mo optic neuropathy 
2 mo optic neuropathy 
6 mo optic neuropathy 
and orbits on CT 
XRT, it MTX, and Ara-C Sensorimotor symptoms; 
optic atrophy and central 
scotomas 
6 mo sensory and cerebellar 
symptoms; intention 
tremor, poor tandem gait, 
right leg vibration loss 
6 weeks vomiting, vertigo, 
tinnitus, unsteady gait 
1 mo loss of OD vision and 
movement; ataxia, 
confusion, right face 
sensory loss; orbital mass 
on MRI 
Ataxia, lower cranial nerve 
palsies, later coma 
Headache, fever, SIADH 
117 WBC; 9 6 8  lymphs 
2,500 WBC; most lymphs XRT, it MTX, and h a - C  Free of disease at  7 mo 
4 WBC; most lymphs 
175 WBC; 98% lymphs 
Aspirin 
None 
Symptoms continue at  4 
Died 3 mo later 
mo 
71 WBC* 
334 WBC; 100% lymphs 
12 WBC; 95% lymphs 
1,100 WBC" 
676 WBC; 100% lymphs 
XRT and it MTX 
it MTX 
Removal of mass 
it MTX and Ara-C 
XRT and it MTX 
No symptoms a t  30 mo 
No symptoms; died after 1 
year of cardiac disease 
Normal postoperative 
neurologic assessment 
No symptoms at  3 mo 
No symptoms a t  2 mo 
0s visual loss; pituitary 
Headache and vomiting 
Headache, right VII and 
bilateral VI palsies, 
ataxia, AD deafness 
mass 
Spastic paraparesis Malignant cytology XRT and it MTX Died of cardiac causes 
days after beginning 
treatment 
Died of pneumonia; CNS 
CLL diagnosed a t  
autopsy 
Died of strangulated 
hernia; CLL diagnosed 
at  autopsy 
Died at  4 years of 
Richter's syndrome 
sparing CNS 
~. 
No neurologic signs or 
symptoms 
11 WBC; 100% lymphs None 
Agitated No lumbar puncture None 
AS deafness, nystagmus, 
ataxia, hyperreflexia 
260 WBC; loo% lymphs XRT, it MTX, and h a - C  
Cases C19 and C20 appear in table 1 as  A6 and A9, respectively. Case C21 is the case report 
* The majority of WBCs are prolymphocytic. 
CLL = chronic lymphocytic leukemia; WBC = white blood cell count; VP = ventriculoperitoneal; XRT = x-ray therapy; it MTX = in- 
trathecal methotrexate; h a - C  = cytarabine; OD = right eye; SIADH = syndrome of inappropriate antidiuretic hormone secretion; 0s  
= left eye; AD = right ear; AS = left ear. 
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an even sex distribution. Presenting features include al- 
tered mental status (acute and chronic), optic neuropathy, 
meningitis with cranial nerve deficits, and cerebellar 
signs. Lumbar puncture was performed in all but one pa- 
tient and showed a lymphocytic pleocytosis of variable de- 
gree, with a range of 4 to 2,500 WBC/mm3 (median, 172). 
In 11 cases in which immunostaining was performed, CSF 
cells were monoclonal and identical to peripheral lympho- 
cytes. Cytologic results were normal in five cases, positive 
for malignant cells without further details in one case, and 
only atypical in four cases. CSF glucose was normal in 11 
cases and low in one, whereas CSF protein was normal in 
six cases and high in seven (median for elevated values, 
107 mg/dl). Only one patient in this group had a serum 
paraprotein. Brain imaging was unremarkable in four 
cases and revealed a mass in three, thickened optic nerves 
in two, and ventriculomegaly in one. Autopsy was per- 
formed in four cases, two of which were detailed. 
Survival time, or time to last followup, was calculated 
from the time of treatment initiation. Survival was corre- 
lated with treatment in the 15 patients who received x-ray 
therapy or intrathecal methotrexate, or both. The dose of 
x-ray therapy was 3000 cGy in half of the cases in which 
the dose was reported, with a range of 1000 to 4000 cGy. 
Those patients who received x-ray therapy did not fare 
better than those who were not radiated. While support for 
cranial x-ray therapy may come from the observation that 
three of the four longest survivors received a dose of 3000 
cGy or greater, two of these long-term survivors had iso- 
lated optic nerve disease. When reported, the number of 
intrathecal methotrexate doses ranged from two to seven 
and the doses ranged from 5 to 12 mg. When maximum 
survival data were analyzed with regard to the use of 
intrathecal methotrexate, a significantly improved sur- 
vival ( p  < .005) was noted when compared with another or 
no treatment. The combination of intrathecal methotrexate 
and x-ray therapy, however, did not yield improved sur- 
vival when compared with the combined group of un- 
treated patients and patients treated with intrathecal 
methotrexate or x-ray therapy alone. Once CLL in the 
CNS was eradicated, it tended not to recur and neurologic 
relapse was not evident in the four longer term survivors 
in whom the cause of death was reported. These survival 
results, however, are based on a review of a relatively 
small and heterogeneous population; larger controlled 
studies will obviously be needed to address these issues 
more completely. 
A nonsignificant trend between increased survival time 
and earlier stage of CLL at the time of CNS infiltration 
was observed. Of the four longest survivors in table 2, two 
were stage 0 and one was stage 11. No significant survival 
advantage was found as a function of age, gender, WBC 
count, Rai stage, or duration of disease. 
The data from 19 lumbar punctures from 18 patients 
with CLL at MGH showed a CSF lymphocyte count of less 
than or equal to 3 cells/mm3 in all cases, except for four 
with a mild lymphocytic pleocytosis (range, 6-60 cells/ 
mm3) and a fifth with Listeria monocytogenes meningitis. 
Two of the four cases with mild CSF lymphocytic pleocyto- 
sis had elevated CSF proteins (68 and 75 mg/dl). Cytologic 
examination was performed in seven patients, two with a 
lymphocytic pleocytosis, and was unremarkable in all 
cases. CSF pleocytosis occurred in patients with stage IV 
disease and in the absence of focal neurologic abnormali- 
ties; significantly, three of the four cases had systemic 
infections at the time of lumbar puncture. One of these 
cases (A6) was autopsied and was found to have infiltra- 
tion of CNS by CLL. 
Discussion. Symptomatic infiltration of the CNS 
by CLL is uncommon and is usually expressed as 
confusional state, meningitis with cranial nerve ab- 
normalities, optic neuropathy, or cerebellar signs. 
Symptomatic CNS involvement occurs at all stages 
of CLL and is accompanied by a CSF lymphocytosis. 
Asymptomatic CNS CLL, however, is common, par- 
ticularly in later stages, with autopsy studies show- 
ing frequencies of >8%,19 45%,lS 50%,17 and 71%.16 
Only 17% of cases in our autopsy series (see table 1) 
had CNS CLL, but this low frequency may reflect the 
paucity of available sections of spinal cord, the most 
commonly involved site.I7 In our lumbar puncture 
series, 18% of asymptomatic patients had lympho- 
cytic pleocytosis, all of whom died with Rai stage IV 
disease within days of lumbar puncture. These cases 
may represent the antemortem analogue of the 
asymptomatic CNS CLL noted in autopsy series. 
Increased risk for symptomatic CNS CLL was not 
predicted by Rai stage, duration of CLL, gender, age, 
immunologic phenotype, or peripheral WBC count 
(see table 2). Symptomatic CNS CLL occurred at all 
Rai stages and in patients from the time of CLL 
diagnosis to 12 years after diagnosis. CNS involve- 
ment was present in equal numbers of men and 
women. The median age of the patients was 63 
years, approximating the median age of patients di- 
agnosed with CLL- 60 years.2 Immunophenotyping 
in 13 patients showed immunoglobulin M heavy 
chains and K light chains in almost all cases, which 
are typical of CLL in genera1.43*44 Only four of the 21 
patients with CNS involvement had a peripheral 
lymphocyte count greater than 1.5 times the mean 
number associated with respective stage of the dis- 
ease.3 
On the other hand, autopsy comparison of sys- 
temic CLL sites between those patients with CNS 
involvement and those without CNS involvement 
disclosed four extraneural sites unique to patients 
with CNS disease: parathyroid, prostate, heart, and 
larynx. CNS infiltration was also associated with a 
greater number of affected systemic sites: All four 
CNS CLL cases with detailed autopsy had CLL in 
five or more organs at the time of death, whereas 
only 1 of 10 autopsies without CNS involvement had 
CLL spread to this many sites. CLL infiltration into 
CNS may therefore be a random event whereby a 
fraction of patients with bulky disease, including leu- 
kemia in skull bone marrow or pen-CNS tissues, will 
suffer CNS involvement. 
CNS infiltration by CLL may also reflect a biolog- 
ically more aggressive neoplasm, since some CLL 
subtypes may be more malignant. For instance, a 
subset of CLL patients with more diffuse bone mar- 
row infiltration and shortened survival have certain 
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chromosomal  aberration^,^^-^' but karyotypic studies 
of CNS CLL have not yet been performed. Alterna- 
tively, transformation of CLL to a more aggressive 
variant or association of CLL with an extraneural 
lymphoma may predispose to CNS involvement. Six 
of the 21 CNS CLL cases (see table 2) had either 
lymphomas or  transformation. However, this fre- 
quency of Richter’s syndrome and prolymphocytic 
transformation is similar to those of other large CLL 
~ e r i e s . ~ . ~  
The mechanism by which CLL cells enter the CNS 
remains unknown. Neuropathologic findings include 
leukemic meningitis, perivascular CLL cells, and 
lymphocytes extravasated with hemorrhage. The 
similarity to  descriptions of ALL in the CNSZ1 sug- 
gests that CLL cells may gain access in an analogous 
manner, by extending along perforating vessels from 
the bone marrow through the dura mater and into 
the subarachnoid space.48 Other investigators postu- 
lated the same mechanism for CNS spread of non- 
Hodgkin’s l y m p h ~ m a . ~ ~ , ~ ~  Consistent with these hy- 
potheses is the observation of a peri-CNS focus of 
CLL in five of the cases (see table 2). ALL may also 
gain entry to the CNS via hemorrhage into brain 
parenchyma,“@ a mechanism which may underlie 
some CNS CLL (case A6, table 1). 
One case in our lumbar puncture series, with a 
normal CSF and no serum paraprotein, was diag- 
nosed with amyotrophic lateral sclerosis (ALS). 
Younger et aP3 reported three patients with CLL and 
ALS or motor neuron disease who also had normal 
CSF cell counts and cytology. A monoclonal gam- 
mopathy was identified in two of the three patients 
of Younger et al,53 but in only one of the 21 patients 
in table 2. The relationship between CLL, ALS, and 
monoclonal gammopathies, however, has not been 
clearly e~tab l i shed .~~ 
The diagnosis of CNS CLL has a number of poten- 
tial pitfalls. First, early in the course, CNS symp- 
toms may occur with a normal peripheral lympho- 
cyte count, necessitating immunophenotyping 
studies of peripheral lymphocytes for diagnosis.54 
Second, routine cytologic evaluation is of limited 
value given the morphologically mature appearance 
of CLL lymphocytes,j5 the limited diagnostic value of 
atypical lymphocytes, and the occurrence of false- 
positive and false-negative results. For instance, in 
one series of CLL patients, the only positive CSF 
cytologies were false-positive.s6 On the other hand, a 
review of antemortem cytology in patients with au- 
topsy-proven leptomeningeal cancer revealed more 
than half to be false-negative.s7 Third, many diseases 
can mimic the clinical and CSF picture of CNS CLL. 
Apart from l y m p h ~ m a , ~ * . ~ ~  however, these produce a 
T-cell-predominant CSF l y m p h o ~ y t o s i s . ~ ~ - ~ ~  Lym- 
phoma can arise in the setting of CLL (Richter’s 
syndrome) and may involve the CNS, but can be 
distinguished clinically from CNS CLL.64 In systemic 
Richter’s syndrome, the diagnosis is suggested by 
fever, weight loss, and painful abdominal m a s ~ e s , ~  
whereas the rare primary CNS Richter’s syndrome 
24 NEUROLOGY 46 January 1996 
features an intracranial mass l e ~ i o n . ~ ~ - ~ ~  Because of 
such potential pitfalls, the importance of immuno- 
phenotyping CSF lymphocytes to reach a diagnosis 
of CNS CLL should be s t r e s ~ e d . ~ ~ . ~ ~  
Our case illustrates that, with treatment, infiltra- 
tion of the CNS by CLL need not have a dire progno- 
sis. The treatment of our patient with intrathecal 
chemotherapy and cranial x-ray therapy resulted in 
a 4-year, neurologically asymptomatic survival. 
Analysis of 21 cases showed a significant increase in 
survival associated with intrathecal chemotherapy 
alone, but not when intrathecal chemotherapy was 
combined with x-ray therapy. For patients who re- 
ceived x-ray therapy alone, the only two long-term 
survivors had disease localized to the optic nerve, 
which may represent a different disease process. 
Given the paucity of data, the role of systemic che- 
motherapy in CNS CLL cannot be ascertained. Sub- 
sequently, conclusive recommendations for therapy 
of symptomatic CNS CLL must await a larger pro- 
spective trial. In addition, asymptomatic patients 
with monoclonal CSF lymphocytosis may also benefit 
from intrathecal chemotherapy, but this, too, must 
await further study. 
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